Amanda Olson

Amanda Olson


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
SCStefan Ciurea
Stefan Ciurea
PKPiyanuch Kongtim
Piyanuch Kongtim
DSDoris Soebbing
Doris Soebbing
PTPrashant Trikha
Prashant Trikha
GBGregory Behbehani
Gregory Behbehani
RCRichard E. Champlin
Richard E. Champlin
In this phase I/II clinical trial, we investigated the safety and efficacy of high doses of mb-IL21 ex vivo expanded donor-derived NK cells to decrease relapse in 25 patients with myeloid malignancies receiving haploidentical stem-cell transplantation (HSCT). Three doses of donor NK cells (1 × 105–1 × 108 cells/kg/dose) were administered on days −2, +7, and +28. Results were compared with an independent contemporaneously treated case-matched cohort of 160 patients from the CIBMTR database.After a median follow-up of 24 months, the 2-year relapse rate was 4% vs. 38% (p = 0.014), and disease-free survival (DFS) was 66% vs. 44% (p = 0.1) in the cases and controls, respectively. Only one relapse occurred in the study group, in a patient with the high level of donor-specific anti-HLA antibodies (DSA) presented before transplantation. The 2-year relapse and DFS in patients without DSA was 0% vs. 40% and 72% vs. 44%, respectively with HR for DFS in controls of 2.64 (p = 0.029). NK cells in recipient blood were increased at day +30 in a dose-dependent manner compared with historical controls, and had a proliferating, mature, highly cytotoxic, NKG2C+/KIR+ phenotype.Administration of donor-derived expanded NK cells after haploidentical transplantation was safe, associated with NK cell-dominant immune reconstitution early post-transplant, preserved T-cell reconstitution, and improved relapse and DFS. TRIAL REGISTRATION: NCT01904136 (https://clinicaltrials.gov/ct2/show/NCT01904136).

24 March 2022 in Blood
Verified
Journal Article
Open access
PDF file
MGMahmoud R. Gaballa
Mahmoud R. Gaballa
PBPinaki Banerjee
Pinaki Banerjee
DMDenái R. Milton
Denái R. Milton
XJXianli Jiang
Xianli Jiang
CGChristina Ganesh
Christina Ganesh
PKPartow Kebriaei
Partow Kebriaei
Patients with B-lineage acute lymphoblastic leukemia (ALL) are at high-risk for relapse after allogeneic hematopoietic cell transplantation (HCT). We conducted a single-center phase 2 study evaluating the feasibility of 4 cycles of blinatumomab administered every 3 months during the first year after HCT in an effort to mitigate relapse in high-risk ALL patients. Twenty-one of 23 enrolled patients received at least 1 cycle of blinatumomab and were included in the analysis. The median time from HCT to the first cycle of blinatumomab was 78 days (range, 44 to 105). Twelve patients (57%) completed all 4 treatment cycles. Neutropenia was the only grade 4 adverse event (19%). Rates of cytokine release (5% G1) and neurotoxicity (5% G2) were minimal. The cumulative incidence of acute graft-versus-host disease (GVHD) grades 2 to 4 and 3 to 4 were 33% and 5%, respectively; 2 cases of mild (10%) and 1 case of moderate (5%) chronic GVHD were noted. With a median follow-up of 14.3 months, the 1-year overall survival (OS), progression-free survival (PFS), and nonrelapse mortality (NRM) rates were 85%, 71%, and 0%, respectively. In a matched analysis with a contemporary cohort of 57 patients, we found no significant difference between groups regarding blinatumomab’s efficacy. Correlative studies of baseline and posttreatment samples identified patients with specific T-cell profiles as “responders” or “nonresponders” to therapy. Responders had higher proportions of effector memory CD8 T-cell subsets. Nonresponders were T-cell deficient and expressed more inhibitory checkpoint molecules, including T-cell immunoglobulin and mucin domain 3 (TIM3). We found that blinatumomab postallogeneic HCT is feasible, and its benefit is dependent on the immune milieu at time of treatment. This paper is posted on ClinicalTrials.gov, study ID: NCT02807883.

6 February 2020 in Blood
Verified
Journal Article
Open access
PDF file
SCStefan Ciurea
Stefan Ciurea
PKPiyanuch Kongtim
Piyanuch Kongtim
AVAnkur Varma
Ankur Varma
GRGabriela Rondon
Gabriela Rondon
JCJulianne Chen
Julianne Chen
RCRichard E. Champlin
Richard E. Champlin
The optimal conditioning regimen for older patients with acute myeloid leukemia (AML) remains unclear. In this study, we compared outcomes of AML patients >60 years of age undergoing allogenic hematopoietic stem cell transplantation at our institution. All 404 consecutively treated patients received 1 of the following conditioning regimens: (1) fludarabine+melphalan 100 mg/m2 (FM100), (2) fludarabine+melphalan 140 mg/m2 (FM140), (3) fludarabine+IV busulfan AUC ≥ 5000/d × 4 d (Bu≥20000), and (4) fludarabine+IV busulfan AUC 4000/d × 4 d (Bu16000). A propensity score analysis (PSA) was used to compare outcomes between these 4 groups. Among the 4 conditioning regimens, the FM100 group had a significantly better long-term survival with 5-year progression-free survival of 49% vs 30%, 34%, and 23%, respectively. The benefit of the FM100 regimen resulted primarily from the lower nonrelapse mortality associated with this regimen, an effect more pronounced in patients with lower performance status. The PSA confirmed that FM100 was associated with better posttransplantation survival, whereas no significant differences were seen between the other regimen groups. In summary, older patients with AML benefited from a reduced-intensity conditioning regimen with lower melphalan doses (FM100), which was associated with better survival, even though it was primarily used in patients who could not receive a more intense conditioning regimen.

11 October 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
QBQaiser Bashir
Qaiser Bashir
DMDenái R. Milton
Denái R. Milton
UPUday R. Popat
Uday R. Popat
PKPartow Kebriaei
Partow Kebriaei
CHChitra Hosing
Chitra Hosing
NPNaveen Pemmaraju
Naveen Pemmaraju

1 May 2021 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
AOAmanda Olson
Amanda Olson
IPIoannis Politikos
Ioannis Politikos
CBClaudio Brunstein
Claudio Brunstein
FMFillipo Milano
Fillipo Milano
JBJuliet Barker
Juliet Barker
JHJoshua A. Hill
Joshua A. Hill
As an alternative stem cell source, cord blood (CB) has many advantages. However, delayed engraftment, lack of transferred immunity, and a significant incidence of acute graft-versus-host disease renders CB transplant (CBT) recipients at high risk of infectious complications. This guidance written by CBT and infectious disease experts outlines evidence-based recommendations for the prevention and treatment of opportunistic infections in adult patients undergoing CBT. Topics addressed include bacterial, fungal, viral, pneumocystis jirovcii and toxoplasmosis prophylaxis, suggested PCR monitoring for viruses, therapy for the most commonly encountered infections after CBT. We review key concepts including the recent important role of letermovir in the prevention of CMV reactivation. In instances where there is a paucity of data, practice recommendations are provided, including the duration of antimicrobial prophylaxis.

12 April 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
JRJeremy L. Ramdial
Jeremy L. Ramdial
RMRohtesh S. Mehta
Rohtesh S. Mehta
RSRima M. Saliba
Rima M. Saliba
AAAmin M. Alousi
Amin M. Alousi
QBQaiser Bashir
Qaiser Bashir
UPUday Popat
Uday Popat